Xihuang Pills Targeting the Warburg Effect Through Inhibition of the Wnt/β-catenin Pathway in Prostate Cancer

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Jul 12

PMID 38994113

Authors

Fengxia Lin

Yan Long

Mingyue Li

Changlong Cai

Yongrong Wu

Xujun You

Xuefei Tian

Qing Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: Prostate cancer, marked by a high incidence and mortality rate, presents a significant challenge, especially in the context of castration-resistant prostate cancer (CRPC) with limited treatment options due to drug resistance. This study aims to explore the anti-tumor effects of Xihuang Pills (XHP) on CRPC, focusing on metabolic reprogramming and the Wnt/β-catenin pathway.

Methods: In vitro and in vivo biofunctional assays were employed to assess the efficacy and mechanisms of XHP. Subcutaneous xenografts of PC3 in mice served as an in vivo model to evaluate XHP's anti-tumor activity. Tumor volume, weight, proliferation, and apoptosis were monitored. Various assays, including CCK8, TUNEL assay, QRT-PCR, and Western Blotting, were conducted to measure metabolic reprogramming, proliferation, apoptosis, and cell cycle in prostate cancer cells. RNA-seq analysis predicted XHP's impact on prostate cancer, validating the expression of Wnt/β-catenin-related proteins and mRNA. Additionally, 58 compounds in XHP were identified via LC-MS/MS, and molecular docking analysis connected these compounds to key genes.

Results: In vitro and in vivo experiments demonstrated that XHP significantly inhibited CRPC cell viability, induced apoptosis, and suppressed invasion and migration. mRNA sequencing revealed differentially expressed genes, with functional enrichment analysis indicating modulation of key biological processes. XHP treatment downregulated Wnt signaling pathway-related genes, including CCND2, PRKCG, and CCN4. Moreover, XHP effectively inhibited glucose uptake and lactate production, leading to reduced HIF-1α and glycolytic enzymes (GLUT1, HK2, PKM2), suggesting its potential in attenuating the Warburg effect. Molecular docking analysis suggested a plausible interaction between XHP's active compounds and Wnt1 protein, indicating a mechanism through which XHP modulates the Wnt/β-catenin pathway.

Conclusion: XHP demonstrated remarkable efficacy in suppressing the growth, proliferation, apoptosis, migration, and invasiveness of prostate tumors. The interaction between XHP's active constituents and Wnt1 was evident, leading to the inhibition of Wnt1 and downstream anti-carcinogenic factors, thereby influencing the β-catenin/HIF-1α-mediated glycolysis.

References

OSullivan A, Mulvaney E, Kinsella B . Regulation of protein kinase C-related kinase (PRK) signalling by the TPα and TPβ isoforms of the human thromboxane A receptor: Implications for thromboxane- and androgen- dependent neoplastic and epigenetic responses in prostate cancer. Biochim Biophys Acta Mol Basis Dis. 2017; 1863(4):838-856. DOI: 10.1016/j.bbadis.2017.01.011. View

Dong Q, Meng P, Wang T, Qin W, Qin W, Wang F . MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One. 2010; 5(4):e10147. PMC: 2854685. DOI: 10.1371/journal.pone.0010147. View

Saad F, Aprikian A, Finelli A, Fleshner N, Gleave M, Kapoor A . 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2022; 16(11):E506-E515. PMC: 9665314. DOI: 10.5489/cuaj.8161. View

Costello L, Franklin R . Citrate metabolism of normal and malignant prostate epithelial cells. Urology. 1997; 50(1):3-12. DOI: 10.1016/S0090-4295(97)00124-6. View

Kelsey R . Prostate cancer: Glycolysis and AR expression as biomarkers. Nat Rev Urol. 2017; 15(1):2. DOI: 10.1038/nrurol.2017.205. View

Chen M, Liu H, Li Z, Ming A, Chen H . Mechanism of PKM2 affecting cancer immunity and metabolism in Tumor Microenvironment. J Cancer. 2021; 12(12):3566-3574. PMC: 8120184. DOI: 10.7150/jca.54430. View

Scaglia N, Frontini-Lopez Y, Zadra G . Prostate Cancer Progression: as a Matter of Fats. Front Oncol. 2021; 11:719865. PMC: 8353450. DOI: 10.3389/fonc.2021.719865. View

Martiny-Baron G, Fabbro D . Classical PKC isoforms in cancer. Pharmacol Res. 2007; 55(6):477-86. DOI: 10.1016/j.phrs.2007.04.001. View

Nivison M, Meier K . The role of CCN4/WISP-1 in the cancerous phenotype. Cancer Manag Res. 2018; 10:2893-2903. PMC: 6118280. DOI: 10.2147/CMAR.S133915. View

10.

Zhang H, Lu H, Xiang L, Bullen J, Zhang C, Samanta D . HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci U S A. 2015; 112(45):E6215-23. PMC: 4653179. DOI: 10.1073/pnas.1520032112. View

11.

Chang A, Chen P, Lin Y, Su C, Liu J, Lin T . Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin α4β1 system. Cancer Lett. 2018; 426:47-56. DOI: 10.1016/j.canlet.2018.03.050. View

12.

Ge A, Yang K, Deng X, Zhao D, Ge J, Liu L . The efficacy and safety of Xihuang Pill/capsule in adjuvant treatment of breast cancer: A systematic review and meta-analysis of 26 randomized controlled trials. J Ethnopharmacol. 2022; 295:115357. DOI: 10.1016/j.jep.2022.115357. View

13.

Lee S, Jeon H, Ju M, Kim C, Yoon G, Han S . Wnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism. Cancer Res. 2012; 72(14):3607-17. DOI: 10.1158/0008-5472.CAN-12-0006. View

14.

Kypta R, Waxman J . Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 2012; 9(8):418-28. DOI: 10.1038/nrurol.2012.116. View

15.

Xu H, Li Y, Yi X, Zheng X, Yang Y, Wang Y . ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression. Mil Med Res. 2023; 10(1):64. PMC: 10714548. DOI: 10.1186/s40779-023-00500-9. View

16.

de la Cruz-Lopez K, Castro-Munoz L, Reyes-Hernandez D, Garcia-Carranca A, Manzo-Merino J . Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Front Oncol. 2019; 9:1143. PMC: 6839026. DOI: 10.3389/fonc.2019.01143. View

17.

Ashton T, McKenna W, Kunz-Schughart L, Higgins G . Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. Clin Cancer Res. 2018; 24(11):2482-2490. DOI: 10.1158/1078-0432.CCR-17-3070. View

18.

Murillo-Garzon V, Kypta R . WNT signalling in prostate cancer. Nat Rev Urol. 2017; 14(11):683-696. DOI: 10.1038/nrurol.2017.144. View

19.

Paul S, Ghosh S, Kumar S . Tumor glycolysis, an essential sweet tooth of tumor cells. Semin Cancer Biol. 2022; 86(Pt 3):1216-1230. DOI: 10.1016/j.semcancer.2022.09.007. View

20.

Jin L, Chun J, Pan C, Alesi G, Li D, Magliocca K . Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. Oncogene. 2017; 36(27):3797-3806. PMC: 5501759. DOI: 10.1038/onc.2017.6. View